Glyxambi

Glyxambi · pharmadog

Patent cliff

source: FDA Orange Book

first barrier falls

Apr 15, 2027

282 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (50)

Dec 8, 2037patentUS 12364700*PED
Dec 8, 2037patentUS 12364700*PED
Jun 8, 2037method-of-use (U-4224)US 12364700
Jun 8, 2037method-of-use (U-4224)US 12364700
Oct 3, 2034patentUS 10258637*PED
Oct 3, 2034patentUS 10258637*PED
Oct 3, 2034patentUS 11090323*PED
Oct 3, 2034patentUS 11090323*PED
Oct 3, 2034patentUS 11833166*PED
Oct 3, 2034patentUS 11833166*PED
Oct 3, 2034patentUS 12433906*PED
Oct 3, 2034patentUS 12433906*PED
Jun 11, 2034method-of-use (U-2290)US 9949998
Jun 11, 2034method-of-use (U-2290)US 9949998
Apr 3, 2034method-of-use (U-2290)US 10258637
Apr 3, 2034method-of-use (U-2290)US 10258637
Apr 3, 2034method-of-use (U-3191)US 11090323
Apr 3, 2034method-of-use (U-3191)US 11090323
Apr 3, 2034method-of-use (U-3776)US 11833166
Apr 3, 2034method-of-use (U-3777)US 11833166
Apr 3, 2034method-of-use (U-4296)US 12433906
Apr 3, 2034method-of-use (U-4296)US 12433906
Aug 11, 2030patentUS 12115179*PED4.1y
Aug 11, 2030patentUS 12115179*PED4.1y
Apr 14, 2030patentUS 8551957*PED3.8y
Apr 14, 2030patentUS 8551957*PED3.8y
Feb 11, 2030method-of-use (U-4023)US 121151793.6y
Feb 11, 2030method-of-use (U-4023)US 121151793.6y
Oct 14, 2029formulationUS 85519573.3y
Oct 14, 2029formulationUS 85519573.3y
Feb 1, 2029patentUS 7579449*PED2.6y
Feb 1, 2029patentUS 7579449*PED2.6y
Aug 1, 2028compositionUS 75794492.1y
Aug 1, 2028compositionUS 75794492.1y
Nov 4, 2027patentUS 11033552*PED1.3y
Nov 4, 2027patentUS 11033552*PED1.3y
Nov 4, 2027patentUS 8673927*PED1.3y
Nov 4, 2027patentUS 8673927*PED1.3y
Oct 15, 2027patentUS 7713938*PED1.3y
Oct 15, 2027patentUS 7713938*PED1.3y
May 4, 2027formulationUS 11033552301d
May 4, 2027formulationUS 11033552301d
May 4, 2027formulationUS 12178819301d
May 4, 2027formulationUS 12178819301d
Apr 15, 2027compositionUS 7713938282d
Apr 15, 2027compositionUS 7713938282d
May 26, 2026patentUS 8883805*PED
May 26, 2026patentUS 8883805*PED
Nov 26, 2025formulationUS 8883805
Nov 26, 2025formulationUS 8883805

(empagliflozin + linagliptin)

indications

all catalysts(21)

News(0)

Report a data issue

Patent cliff

patents (50)

comments(0)

🐶 often sniffed alongside

Trials studying (empagliflozin + linagliptin)